Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition, Collaboration Agreements and Other (Details Narrative)

v3.23.1
Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 08, 2022
Nov. 19, 2020
Dec. 12, 2019
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Deferred revenue [1]           $ 721
Revenue       1,096    
BioNTech Agreement [Member]              
Fees received $ 2,750            
Deferred revenue $ 2,750            
Revenue recognized       688      
Revenue       375      
CFF Agreement [Member]              
Grants receivable       3,600      
Additional milestone payment       4,500      
CFF Agreement [Member] | Accrued Liabilities [Member]              
Other Liabilities       $ 0     $ 88
CFF Agreement [Member] | Cystic Fibrosis Foundation [Member]              
Therapeutics development award   $ 4,200          
Proceeds from award   $ 484          
Additional milestone payment           $ 321  
Genentech Feasibility Study Agreement [Member] | Genentech [Member]              
Revenue     $ 33        
Agreement description     Genentech paid the Company a total of $100 for the development of three molecules, or $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.        
Aggregate revenue     $ 100        
[1] At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 was related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).